Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes , chronic myelomonocytic leukemia , or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.

http://www.news-medical.net/news/20130321/Researchers-complete-phase-II-clinical-trial-of-dasatinib-for-patients-with-higher-risk-MDS.aspx